Introduction {#Sec1}
============

In recent years, several agents have been developed that inhibit the epidermal growth factor receptor (EGFR), which plays a central role in growth of certain cancers. Monoclonal antibodies (mAbs; e.g., cetuximab, panitumumab, necitumumab) and tyrosine kinase inhibitors (TKIs; e.g., erlotinib, gefitinib, lapatinib, afatinib) blocking different EGFR targets are therefore an indispensable part of cancer treatment. EGFR inhibitors are used to treat advanced or metastatic non-small cell lung cancer (afatinib, erlotinib, gefitinib, necitumumab), pancreatic cancer (erlotinib), breast cancer (lapatinib), colon cancer (cetuximab, panitumumab), and head and neck cancer (cetuximab). Compared with cytotoxic chemotherapy with taxanes, fluoropyrimidines, and platinum compounds that are known to be associated with multiple adverse events (AEs) such as fatigue, pain, nausea and emesis, hematologic toxicity, and neuropathy, EGFR inhibitors may have a lower impact on health-related quality of life (HRQOL). However, due to the role of EGFR in skin biology, all EGFR inhibitors are associated with a variety of dermatologic AEs (dAEs), e.g., acneiform (papulopustular) rash, hair changes (hair loss, facial hypertrichosis, eyelash trichomegaly), pruritus, mucositis, xerosis and fissures, and paronychia (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Dermatologic adverse events associated with EGFR inhibitors: **a** paronychia, **b** xerosis, and **c** acneiform rash

Due to increased incidence of dAEs associated with targeted cancer therapies, a large volume of publications have focused on these toxicities. To get an overview of the current research status and to identify knowledge gaps, this article summarizes the main findings on this topic. It is noteworthy that the severity of patients' AEs, including those of the skin \[[@CR1]\], does not necessarily correlate with the amount to which patients are actually distressed. This requires a special focus on patient-reported outcomes and patients' HRQOL as part of this literature analysis.

Methods {#Sec2}
=======

In the first step, a structured literature search was conducted with the aim of collecting all published articles containing information on ≥1 of the following topics: (1) types of skin toxicities and incidences, (2) toxicity grading systems, (3) prevention and treatment strategies, (4) correlation of rash and efficacy of anti-EGFR therapies, (5) impact of rash on QOL/patient-reported outcomes, and (6) patient acceptance of dAEs/patient adherence.

The literature search was conducted using MEDLINE/PubMed (1st January 1983 to 31st January 2014). MEDLINE contained 17,024,638 articles published during this time period. In addition, further articles were identified by manually searching the references of articles obtained through the electronic search. The search was performed using keywords combined with appropriate operators (AND, OR): (1) *skin toxicity* (OR skin rash, exanthema, acneiform eruption, dermatology, skin disease) AND (2) *EGFR inhibitors* (OR anti-EGFR, cancer therapy, monoclonal antibodies, tyrosine kinase inhibitors, TKIs, cetuximab, Erbitux, panitumumab, Vectibix, erlotinib, Tarceva, gefitinib, Iressa, lapatinib, Tykerb, Tyverb, necitumumab, afatinib, Giotrif, Gilotrif, trametinib, Mekinist, pertuzumab, Jevtana) AND (3) *patient acceptance* (OR patient-related outcome, patient tolerance, patient reactions, patient compliance, patient adherence, patient persistence, treatment discontinuation, treatment persistence, dose reduction, interrupted treatment, therapy decision, quality of life, QOL, utility assessment, risk-benefit balance). In total, 71 publications (including 10 reviews, guidelines, and recommendations; 60 research studies; and 1 book) published from 2004 to 2014 were identified for consideration in the final evidence review.

Results {#Sec3}
=======

Due to the availability of data from clinical studies (interventional as well as non-interventional), the majority of published articles concentrate on the incidence of different dAEs, on treatment and prevention strategies, and on the putative correlation between dAEs and efficacy. Based on the growing knowledge about incidence of skin toxicities, further topics appear in recent publications that are more patient oriented: the impact on QOL and the development of grading systems to assess this impact through patient-reported outcomes and questionnaires. Only a small number of publications refer to patient acceptance of dAEs or to patient adherence to therapies associated with dAEs.

Here, we concentrate on the major findings for each topic, with a more detailed focus on patient-reported outcomes and patients' HRQOL. Other findings are summarized elsewhere in more detail \[[@CR2]--[@CR6]\].

Incidence of dermatologic adverse events {#Sec4}
----------------------------------------

Skin rash/acneiform rash is the most frequently observed dAE associated with EGFR inhibitors and can be observed in the majority of patients treated with mAbs (Table [1](#Tab1){ref-type="table"}). Other prominent dAEs induced by EGFR inhibitors are xerosis, pruritus, nail changes, mucositis, fissures of fingertips and toes, and hair changes \[[@CR3]--[@CR16]\]. It has been claimed that severe dAEs may result in significant physical and emotional discomfort \[[@CR15]\]. However, the incidence of these toxicities alone does not allow drawing conclusions on their impact on QOL. Based on the reported high incidence of dAEs, the authors conclude that dermatologic toxicities associated with EGFR inhibitors underscore the importance of dermatologic evaluation, prevention, and treatment of these toxicities \[[@CR17]\].Table 1Overview of dermatologic adverse events in patients with cancer treated with EGFR inhibitors \[[@CR4], [@CR5], [@CR12], [@CR14], [@CR33], [@CR74]\]TreatmentSkin rash (%)Xerosis (dry skin) (%)Pruritus (itching) (%)Paronychia (nails) (%)Hair abnormalities/alopecia (%)Mucositis (%)mAbs Cetuximab  All grades80491016Alopecia: 5\<1  Grade 3/41041\<1Trichomegaly: 12\<1 Panitumumab  All grades774663256  Grade 3/44022Trichomegaly: 6\<1 Necitumumab  All grades652421N/AN/AN/A  Grade 3/4370N/AN/AN/ATKIs Afatinib  All grades73151634  Grade 3/413\<1\<14 Erlotinib  All grades75121314Alopecia: 619  Grade 3/490\<1\<1Trichomegaly: 11\<1 Gefitinib  All grades471183--2  Grade 3/420\<1\<1--1 Lapatinib  All grades47131211Alopecia: 1344  Grade 3/43\<1\<1\<10Overall All grades47--10010--498--573--25Alopecia: 0--130--44 Grade 3/41--100--70--20--2Trichomegaly: 0--120--1Reported rates are derived from different studies in various diseases, combinations, and different durations of treatment*EGFR* epidermal growth factor receptor, *mAb* monoclonal antibody, *N/A* not available, *TKI* tyrosine kinase inhibitor

Grading systems for skin rash {#Sec5}
-----------------------------

Accurate grading of papulopustular rash associated with anti-EGFR therapy is essential to ensure timely and appropriate interventions. Currently, the Common Terminology Criteria for Adverse Events (CTCAE) is a widely used classification system in clinical trials. The most recent version (version 4.03) of this tool was published in June 2010 \[[@CR18], [@CR19]\]. For example, severe skin rash (grade 3) is defined by papules and/or pustules covering ≥30 % of the body surface area, limited self-care activities of daily living, or associated local superinfection (oral antibiotics indicated). Grade 2 skin rash is described to be "associated with psychosocial impact," but a validated tool to assess the degree of psychosocial impact is not part of the CTCAE. In addition, the CTCAE scale does not separately characterize the specific dermatologic toxicities observed with EGFR inhibitor therapy (xerosis, pruritus, paronychia, hair abnormalities, and mucositis).

In addition to the CTCAE, several alternative EGFR inhibitor- focused grading systems for dAEs have been proposed in recent years \[[@CR2], [@CR20]--[@CR22]\]. Although several scaling systems exist, no studies have investigated how much these tools are actually used. In particular, it is not known how often current diagnosis of dAEs systematically includes assessment of restrictions in daily and social activities, emotional stress, and the need for dermatologic treatment.

Prevention and treatment strategies {#Sec6}
-----------------------------------

Much of the literature about EGFR inhibitor-induced skin toxicities contains prevention and treatment recommendations \[[@CR1], [@CR2], [@CR7], [@CR12], [@CR15], [@CR23]--[@CR29]\]. Based on the recommendations of the Multinational Association for Supportive Care in Cancer Skin Toxicity Study Group, clear guidelines for prevention and treatment have been developed, e.g., for skin rash (prevention: hydrocortisone, minocycline; treatment: alclometasone, fluocinonide, clindamycin, doxycycline, minocycline, isotretinoin), radiation-induced dermatitis, pruritus, oral complications, xerosis and fissures, and paronychia. The clinical practice guidelines are summarized in detail elsewhere \[[@CR15]\]. However, no studies have investigated how often patients with cancer treated with EGFR inhibitors actually receive a preventive treatment, the criteria used to determine whether patients receive a preventive treatment, and how much dermatologists are involved in treatment recommendations \[[@CR30]\].

Correlation of skin rash and efficacy of anti-EGFR therapies {#Sec7}
------------------------------------------------------------

Moreover, numerous studies confirmed that skin rash (the frequently occurring type of dAE caused by EGFR inhibitors) is associated or correlated with efficacy of the EGFR inhibitor therapy \[[@CR2], [@CR8], [@CR9], [@CR13], [@CR20], [@CR24], [@CR29]--[@CR52]\]. Efficacy measures investigated in such studies are usually response rate or overall survival (OS), e.g., by comparing response rates or median OS between subgroups of patients with no rash, grade 1 rash, and grade ≥2 rash. However, the findings do not allow the conclusion that the therapy is not effective if no or only mild dAEs occur. In addition, it is not known whether patients with an advanced stage of cancer actually prefer a cancer therapy with a high risk of severe skin rash even though the therapy does not cure the disease in the majority of cases.

Impact of skin rash on quality of life/patient-reported outcomes {#Sec8}
----------------------------------------------------------------

Eleven surveys (2007--2013) that report results on the impact of skin rash on HRQOL were identified and analyzed. Ten surveys report a negative impact on HRQOL, particularly with higher grades of skin rash (grade ≥2) \[[@CR38], [@CR53]--[@CR61]\]. Only one author reports no correlation of grade of skin toxicity with QOL regarding the difference in QOL between patients with skin rash grade 0/1 vs grade ≥2 \[[@CR47]\]. However, this study used the EQ-5D to assess QOL, and the EQ-5D is a general QOL measure that is not tailored to measure QOL related to skin conditions.

To assess HRQOL, different tools are available as follows: Skindex-16 \[[@CR38], [@CR62]\], Skindex-29 \[[@CR62]\], Functional Assessment of Cancer Therapy (FACT)-EGFRI-18 \[[@CR54]\], DIELH \[[@CR60]\], Dermatology Life Quality Index (DLQI) \[[@CR56], [@CR63]\], and general assessments of QOL through HRQL \[[@CR64]\] or EQ-5D \[[@CR47]\].

The two Skindex questionnaires (1 with 16 items, 1 with 29 items) measure comprehensively the effects of skin disease on different dimensions of HRQOL: symptoms (e.g., itching, burning sensations), emotions (e.g., frustration, embarrassment, feeling depressed), and functions (e.g., effect on relationships, daily activities, and work). Skindex-16 is a brief version (one-page questionnaire) assessing not only how often patients have a particular experience but also how much they are bothered by it. Each question asks the patient to quantify how much a specific aspect of his or her skin condition bothered him or her in the week prior to administration of the questionnaire. The overall score can be further divided into three subscales: the patient's emotional state, symptom severity, and functioning state. All published studies using Skindex reported a lower QOL for patients with papulopustular rash. The correlation is based on the concordance between QOL score and graded severity using CTCAE: the higher the graded severity of rash, the lower the reported QOL. The impact is highest on the emotional dimension \[[@CR38]\]. Furthermore, QOL is affected more in younger patients aged \<50 years. Targeted therapies associated with dAEs are also more often associated with a lower QOL than non-targeted therapies \[[@CR58]\], again with strongest expression in the emotions domain.

Studies using scales other than Skindex to measure HRQOL support the hypothesis of the negative impact of dAEs on QOL as well, but with smaller sample sizes. For example, one study using DLQI \[[@CR56]\] identified 4 out of 16 patients with skin rash grade ≥2, and all reported a moderate to strong impact on QOL. Finally, FACT-EGFR-18 is a validated instrument with18 items, including subscales for physical well-being (e.g., "My skin or scalp itches"), social/emotional well-being (e.g., "My skin condition affects my mood"; "I avoid going out in public because of how my skin looks"), and functional well-being (e.g., "My skin condition interferes with my ability to sleep") \[[@CR54]\]. A small sample with 10 patients treated with EGFR inhibitors showed significant correlations between intensity of dAEs and QOL.

Although the results clearly support the assumption that the QOL of patients with cancer is affected by the occurrence of dAEs induced by EGFR inhibitors (in particular, skin rash grade ≥2), the sample sizes in the current literature are rather small, and the use of these tools is currently not part of standard clinical practice. The results mainly provide insights on how the emotional and social dimensions of life are affected by physical conditions, but no conclusions can be drawn regarding whether patients and/or physicians are less motivated to use cancer therapies causing both (severe) dAEs and worsened psychosocial well-being.

Patient acceptance of skin toxicities/patient adherence {#Sec9}
-------------------------------------------------------

Only a few publications report on patient acceptance of dAEs caused by EGFR therapies \[[@CR5], [@CR56], [@CR65]--[@CR69]\]. Most of the studies provide data about the frequency of dose reductions or therapy terminations due to skin toxicities. The rate of dose reductions or treatment terminations can be interpreted as an indicator of low patient adherence and probably also as an indicator of low patient acceptance. In five surveys on erlotinib, dose reductions in 11 to 17 % of patients were necessary due to skin toxicities; 4 to 14 % of patients terminated the treatment (Table [2](#Tab2){ref-type="table"}).Table 2Overview of dose reductions and termination of treatment in EGFR therapies due to skin rashReferenceEGFRINumber of patientsDose reduction, % of patientsReduced daily dose (mg/day)Treatment termination or interruption, % of patientsShepherd et al. (2005) BR.21 study \[[@CR67]\]Erlotinib4271210014Tiseo et al. (2009) Italian EAP \[[@CR68]\]Erlotinib65119^a^50--1004^a^Reck et al. (2010) TRUST study \[[@CR66]\]Erlotinib6580111005Binder et al. (2012) \[[@CR65]\]Erlotinib5317\
17100\
50--758Yeo et al. (2010) \[[@CR69]\]Erlotinib710025N/A*EAP* expanded-access program, *EGFR* epidermal growth factor receptor, *EGFRI* epidermal growth factor receptor inhibitor, *N/A* not available^a^Dose reductions or treatment termination due to all adverse events (no separate value for skin rash available)

Across all studies, treatment was interrupted by the patients mainly because of grade ≥3 toxicities, but there are no published data clarifying whether the decision was made by the patients or the physicians. In a large study including 427 patients treated with erlotinib \[[@CR67]\], 12 % of patients required dose reductions to 100 mg daily because of drug-related rash, and 14 % required treatment interruptions because of rash. Nine percent of the total erlotinib group had grade ≥3 rash. According to this study, treatment modification was not recommended for grade 1 or 2 rash \[[@CR67]\]. For grade 3 rash, treatment was withheld, the rash was treated symptomatically, and erlotinib was restarted at a dose of 100 mg daily when the rash was grade ≤1.

Only one study assessed patient concerns about dAEs during treatment irrespective of dose modifications or terminations \[[@CR56]\]. In this retrospective survey, 16 patients treated with EGFR inhibitors were asked whether, at some time during the treatment, they had wanted to stop treatment for dermatologic reasons. Three patients answered positively. Two of them had experienced grade ≥3 dAEs, justifying treatment discontinuation according to the clinical grade. One patient, however, wanted to stop EGFR inhibitors because of the severe psychological impact of facial skin and hair modifications despite moderate clinical grading of these changes. None of the 13 remaining patients wanted to stop therapy because of cutaneous toxicities, including four patients with grade 3 dAEs who stopped treatment following medical advice because of severe dAEs. In total, in 6 of the 16 patients (37 %), EGFR inhibitors had been temporarily discontinued: three patients on cetuximab (grade 3 folliculitis), two patients on erlotinib (one with grade 3 folliculitis, one with atypical rash and paronychia), and one on panitumumab (painful digital fissures). Although the survey included a rather small number of patients (*n* = 16), the results showed that some patients considered stopping therapy even though they did not actually stop, and some patients did not consider stopping therapy even though they did stop on the advice of healthcare professionals.

Considering the few studies addressing low patient adherence, it is clear that patient acceptance of skin toxicities is only indirectly addressed by studies investigating dose modifications or treatment discontinuations due to AEs. High-grade skin toxicity leads to treatment interruption and dose reduction. Data on dose adjustments are usually assessed as a part of clinical trials (not as primary endpoints), but the incidence of dose adjustments cannot be equated with low patient acceptance of AEs because more patients may be psychologically distressed than indicated by the number whose dose was changed or who terminated treatment.

Discussion {#Sec10}
==========

This literature survey clearly demonstrates that there is abundant information about the incidence of dAEs caused by EGFR inhibitors (\>70 % all grades; 9--10 % grade 3; higher incidence in mABs than in TKIs). Accordingly, prevention and treatment of skin toxicities is an important topic in clinical practice, at least at the level of treatment guidelines. Based on correlation studies, the occurrence and the severity of dAEs are associated with higher response rates and a survival benefit, but dAEs are also associated with lower HRQOL, particularly for severe skin rash. Several tools are available that can be used to measure HRQOL in patients treated with EGFR inhibitors, but it is unclear to what extent these tools are actually used. The incidence of dose reductions and treatment terminations due to dAEs (mainly skin rash) support the hypothesis that the dAEs that occur exceed a threshold of acceptance. However, the data are often unplanned by-products of larger clinical trials that are focused on response rates, progression-free survival, or OS as primary endpoints.

Of 70 publications on skin toxicities associated with the use of EGFR inhibitors, there is only one study (with only 16 patients) that directly addresses patient concerns about dAEs during treatment \[[@CR56]\]. The available tools used for grading dAEs and assessing their impact on QOL refer mainly to the severity of reported dAEs and their impact on emotional, social, or functional aspects of QOL. However, they do not reflect how patients actually think about dAEs, how patients evaluate these events compared with other AEs caused by cancer therapies, and to what extent these events are accepted in relation to the efficacy of cancer therapies. In addition, the available data do not provide any insights on the physician-patient interaction before, during, or after drug treatment. In clinical practice, balancing different benefits and disadvantages of treatment options occurs every day when treatment decisions are made, and the opinions of both healthcare practitioners and patients need to be considered. Therefore, we conclude that the next generation of research projects on dAEs caused by cancer therapies should address missing information regarding the following issues: *(1) lack of patient voice*, *(2) physician-patient communication regarding dAEs*, *(3) acceptance of (severe) skin toxicities compared with other AEs*, and *(4) balancing the risk of (severe) skin toxicities and the efficacy of the therapy*.

(1) Overcome the issue of the missing patient voice {#FPar1}
---------------------------------------------------

To better understand patients' beliefs regarding dAEs, future studies on dAEs should assess the experiences and opinions of patients with cancer regarding the occurrence of skin rash or other skin toxicities during treatment. For this purpose, FACT-EGFRI-18 was developed to assess dermatologic symptoms associated with EGFR inhibitors. In addition, gathering information through patient interviews is useful, either retrospectively after treatment or during treatment with EGFR inhibitors. What are patients' first reactions when dAEs occur, and to what extent are patients prepared by physicians for the occurrence of dAEs? Which aspects of dAEs are most bothersome (e.g., itching, dry skin, skin rash on the face vs other regions, duration of skin rash)? Do patients accept these AEs as part of the cancer treatment? What has been done to prevent or treat dAEs in patients treated with EGFR inhibitors? Which activities of daily living are affected? The main benefit of gathering this information is to find leverage points for prevention and patient education, similar to patient education on other AEs, such as alopecia, anemia, and neutropenia \[[@CR7], [@CR9], [@CR21], [@CR22], [@CR31], [@CR35], [@CR61], [@CR64], [@CR70], [@CR71]\].

(2) Gather information on physician-patient communication regarding dAEs {#FPar2}
------------------------------------------------------------------------

Communication about skin toxicities like skin rash includes various aspects: informing the patient about dAEs before starting the therapy (or during therapy decision), deciding about preventive measures, using patient brochures (Supplemental Figure [1](#MOESM1){ref-type="media"}), communicating with the patient when dAEs occur, and deciding about treatment of dAEs (which includes referrals to dermatologists). In the current publications, none of these aspects of physician-patient communication were investigated. For example, in the phase of patient education before starting the therapy, it is currently unknown how many patients treated with EGFR inhibitors are informed about the risk of dAEs. In addition, published data do not contain any information on how physicians explain dAEs (for example, skin rash) to their patients: using words like "rash," "acne," or "pustules" may lead to a patient's incorrect understanding of this type of AEs. To what extent are patients shown pictures to demonstrate what a skin rash looks like? What else is said to the patient regarding dAEs, e.g., about itching and inflammation of skin areas and whether this is an indicator of efficacy or at least that the agent is active? One goal of future research will be to describe in detail what physicians tell their patients and what sticks in the minds of the patients. Based on the results of such surveys, it would be easier to make the current communication more effective by emphasizing certain aspects of skin rash that are currently not well understood by patients \[[@CR42], [@CR55], [@CR72]\].

(3) Provide insights into acceptance of (severe) skin toxicities compared with other AEs {#FPar3}
----------------------------------------------------------------------------------------

Because studies have focused on dAEs, the impact of these events on QOL compared with that of other AEs has been insufficiently investigated. The same concern applies to patient acceptance of dAEs compared with other AEs. Such information could be quite easily gathered, for example, through paired-comparison methodologies, with the patient asked to select the most bothersome AE from two options, or to select one therapy among several treatment options that differ only regarding their AEs (e.g., severe skin rash vs hair loss vs fatigue/tiredness vs nausea/vomiting). To get valid results, it will be important to conduct such a survey with patients with cancer who have been treated with EGFR inhibitors and who already experienced dAEs. Conducting the same exercise with treating physicians would provide insights about differences between physicians' and patients' perception of the burden of AEs. For example, physicians observing dAEs with different grades among many patients might overestimate the bothersome impact of dAEs compared with patients.

(4) Collect information on balancing the risk of (severe) skin toxicities and the efficacy of the therapy {#FPar4}
---------------------------------------------------------------------------------------------------------

Treatment decisions are not made simply by selecting one therapy with the least bothersome AE. In clinical practice, the decision process is influenced by multiple factors, for example, tumor histology, tumor stage, rate of progression, patient's performance status, patient features (e.g., age, sex, smoking status), cancer therapies used in earlier treatment lines, clinical trial results of treatment options, structure of the patient samples in clinical trials, availability of anticancer drugs, and personal experience with the available drugs. Once a list of the most suitable treatment options for an individual patient is determined, one option is selected based on the balance between acceptable AEs and expected efficacy. For example, a patient with stage IV non-small cell lung cancer could be treated in the first line with an EGFR inhibitor (one of the available TKIs) or with chemotherapy. The TKI is associated with a certain risk of skin rash or other AEs (e.g., diarrhea). As the currently approved TKIs are efficacious regarding the chance of controlling the tumor or prolonging life for a certain number of months, the decision seems to be easy. Not accepting the risk of severe skin rash (occurring in about 9 % of the patients treated with oral TKIs) would mean that the patient and the treating team of physicians would forgo the chance of controlling the tumor. Because many patients with advanced lung cancer are treated with TKIs (particularly when their disease is *EGFR*-mutation positive), the decision between avoiding skin rash and accepting it (with the chance of controlling the disease for a certain amount of time) is obviously toward skin rash acceptance; otherwise, patients would not be treated with EGFR inhibitors. The psychological reasons for this decision are probably the fact that skin rash is not life-threatening (no case of grade 5 skin rash has been reported), the symptoms are transitional (maximum intensity after 2 to 3 weeks, total duration until crusting of eruptions and the phase of dry skin 5 to 8 weeks \[[@CR6], [@CR21], [@CR72], [@CR73]\]), physicians do not describe grade 3 severe skin rash in detail, or less informed patients associate it with juvenile acne. However, so far, no study has been conducted that systematically investigates the balance between seeking efficacy and avoiding severe skin rash risk. What probability of severe skin rash is accepted at a given level of efficacy? And how to balance tumor control with a given probability of severe skin rash? Such studies should involve both physicians and patients with an advanced stage of tumor development in order to compare both groups.

Conclusion {#Sec11}
==========

More research is needed on the impact of dAEs on patients' acceptance of cancer treatments. Although reduced HRQOL, dose modifications, and therapy discontinuations have been reported in patients with severe skin toxicity, systematic studies are missing that compare the impact of dAEs with the impact of other toxicities on therapy decisions from both the physician's and patient's view.

To overcome the issue of the rare patient voice, the next generation of patient-related outcome studies should provide deeper insights into how the risk of (severe) skin rash is accepted by both physicians and patients, and how efficacious a cancer therapy should be at a given risk of severe skin rash. Such insights might especially highlight the balance between AEs and efficacy that needs to be achieved for a cancer drug to be perceived as valuable by patients and physicians.
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